Daily News: March 9, 2015

Hastings Hires M&A Heavyweight

Paul Hastings announced David Shine, best known for his work on healthcare mega mergers, joined the firm as a partner and chair of the firm’s M&A practice in New York. He joins from Fried Frank, where he was co-head of the M&A practice.

“David’s arrival advances our goal of bringing on talented lawyers in key areas as we continue to grow our practices across our global network,” said Barry Brooks, chair of the New York office of Paul Hastings. “Our lateral partner investments have helped us to become a major player in the Leveraged Finance, Latin America and White Collar and Investigations practices, and David’s addition will allow us to add M&A to that list,” he added.

“We continue to grow our M&A capabilities, with a focus on key industries, such as life sciences and healthcare, and David’s addition marks another important step in our efforts,” said Elizabeth Noe, chair of the corporate practice at Paul Hastings. “Adding a well-known M&A lawyer like David, who has advised on some of the largest and most complex healthcare transactions, positions Paul Hastings to capitalize on the resurgence that’s taking place in the M&A market.”

Fried Frank has been, and will certainly continue to be, a great firm at which to practice M&A and so my decision to leave was very difficult,” said Shine. “But I am extremely excited about the challenge and the opportunity to help broaden and deepen the M&A practice at Paul Hastings.
The Paul Hastings platform, with its global reach, offers me a significant change from the more geographically focused approach at Fried Frank.”

Shine’s practice is focused on M&A, private equity investments, and joint venture transactions. He has substantial experience in the healthcare, aerospace and defense, energy, telecom and financial services industries. Representative clients have included Merck, Northrop Grumman, GE Capital, Medco Health Solutions and Vodafone Group.

Shine was named a Dealmaker of the Week by The American Lawyer for his role advising Merck in its $41 billion merger with Schering-Plough. Shine is consistently recognized as a leading individual by Chambers USA America’s Leading Lawyers for Business and Chambers Global The World’s Leading Lawyers for Business in CorporateM&A. He is also consistently recognized by Legal 500 in M&A Mega-Deals.